Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
作者信息
Pospisilova Sarka, Sutton Lesley-Ann, Malcikova Jitka, Tausch Eugen, Rossi Davide, Montserrat Emili, Moreno Carol, Stamatopoulos Kostas, Gaidano Gianluca, Rosenquist Richard, Ghia Paolo
机构信息
Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
出版信息
Haematologica. 2016 Mar;101(3):263-5. doi: 10.3324/haematol.2015.139246.
Abstract
摘要
相似文献
1
Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?慢性淋巴细胞白血病预后评估的创新：我们能在TP53基因分析之外走多远？
Haematologica. 2016 Mar;101(3):263-5. doi: 10.3324/haematol.2015.139246.
2
Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.IGHV 突变的慢性淋巴细胞白血病患者的表型异质性具有预后影响，并确定了一个对 BTK 和 PI3Kδ 抑制敏感性增加的亚组。
Leukemia. 2015 Mar;29(3):744-7. doi: 10.1038/leu.2014.308. Epub 2014 Oct 28.
3
B-cell receptor inhibitors in chronic lymphocytic leukemia.慢性淋巴细胞白血病中的B细胞受体抑制剂
Clin Adv Hematol Oncol. 2011 Aug;9(8):605-6.
4
The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.慢性淋巴细胞白血病的突变特征及其对预后和治疗的影响。
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):329-337. doi: 10.1182/asheducation-2017.1.329.
5
[Targeted treatment of chronic lymphocytic leukaemia].[慢性淋巴细胞白血病的靶向治疗]
Ugeskr Laeger. 2014 Apr 7;176(15).
6
Targeted therapy in chronic lymphocytic leukemia: past, present, and future.慢性淋巴细胞白血病的靶向治疗：过去、现在和未来。
Clin Ther. 2013 Sep;35(9):1258-70. doi: 10.1016/j.clinthera.2013.08.004.
7
Chronic lymphocytic leukaemia.慢性淋巴细胞白血病。
Lancet. 2018 Apr 14;391(10129):1524-1537. doi: 10.1016/S0140-6736(18)30422-7. Epub 2018 Feb 21.
8
Clonal dynamics in chronic lymphocytic leukemia.慢性淋巴细胞白血病中的克隆动力学。
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):466-475. doi: 10.1182/hematology.2019000367.
9
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.伊布替尼治疗中断的病因及慢性淋巴细胞白血病患者的结局。
JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218.
10
Ibrutinib-Induced Lymphocytosis: Cytological Features.依鲁替尼诱导的淋巴细胞增多症：细胞学特征
Acta Haematol. 2017;137(1):55-57. doi: 10.1159/000452437. Epub 2016 Dec 14.
引用本文的文献
1
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study.慢性淋巴细胞白血病中亚克隆 TP53 突变的频谱：一项下一代测序回顾性研究。
Hematol Oncol. 2022 Dec;40(5):962-975. doi: 10.1002/hon.3063. Epub 2022 Aug 18.
2
Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions.BCL-2抑制剂维奈托克治疗反应的潜在生物标志物：现状与未来方向
Cancers (Basel). 2021 Jun 14;13(12):2974. doi: 10.3390/cancers13122974.
3
Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods.慢性淋巴细胞白血病患者体细胞TP53突变和17p缺失的检测：当前方法综述
Hematol Transfus Cell Ther. 2020 Jul-Sep;42(3):261-268. doi: 10.1016/j.htct.2020.05.005. Epub 2020 Jun 25.
4
aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.慢性淋巴细胞白血病的畸变：诊断改进的临床意义概述。
Haematologica. 2018 Dec;103(12):1956-1968. doi: 10.3324/haematol.2018.187583. Epub 2018 Nov 15.
5
The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.慢性淋巴细胞白血病的突变特征及其对预后和治疗的影响。
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):329-337. doi: 10.1182/asheducation-2017.1.329.
6
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of deletions.伴有复杂核型的慢性淋巴细胞白血病患者即使没有缺失也显示出不良预后。
Oncotarget. 2017 Apr 21;8(33):54297-54303. doi: 10.18632/oncotarget.17350. eCollection 2017 Aug 15.
7
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.用利托菌素诱导血小板聚集以监测接受依鲁替尼治疗的慢性淋巴细胞白血病患者的出血倾向。
Leukemia. 2017 May;31(5):1117-1122. doi: 10.1038/leu.2016.316. Epub 2016 Nov 2.
8
Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors.携带定型B细胞受体的慢性淋巴细胞白血病亚群中复发性基因突变的不同谱。
Haematologica. 2016 Aug;101(8):959-67. doi: 10.3324/haematol.2016.141812. Epub 2016 May 19.
本文引用的文献
1
Mutations driving CLL and their evolution in progression and relapse.驱动慢性淋巴细胞白血病的突变及其在疾病进展和复发中的演变。
Nature. 2015 Oct 22;526(7574):525-30. doi: 10.1038/nature15395. Epub 2015 Oct 14.
2
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.存在多种复发突变可导致复发/难治性 CLL 的临床试验结局不佳。
Blood. 2015 Oct 29;126(18):2110-7. doi: 10.1182/blood-2015-05-647578. Epub 2015 Aug 27.
3
Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.解析慢性淋巴细胞白血病的分子格局：疾病演变的时间框架
Haematologica. 2015 Jan;100(1):7-16. doi: 10.3324/haematol.2014.115923.
4
Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.慢性淋巴细胞白血病的靶向新一代测序：一种高通量且量身定制的方法将促进其在临床环境中的应用。
Haematologica. 2015 Mar;100(3):370-6. doi: 10.3324/haematol.2014.109777. Epub 2014 Dec 5.
5
Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.慢性淋巴细胞白血病中TP53突变的治疗驱动克隆进化的详细分析
Leukemia. 2015 Apr;29(4):877-85. doi: 10.1038/leu.2014.297. Epub 2014 Oct 28.
6
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.反复出现的突变可改善慢性淋巴细胞白血病的预后。
Leukemia. 2015 Feb;29(2):329-36. doi: 10.1038/leu.2014.196. Epub 2014 Jun 19.
7
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.伊布替尼与奥法妥木单抗治疗既往治疗的慢性淋巴细胞白血病。
N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.
8
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.慢性淋巴细胞白血病的基因突变与治疗结果：CLL8 试验结果。
Blood. 2014 May 22;123(21):3247-54. doi: 10.1182/blood-2014-01-546150. Epub 2014 Mar 20.
9
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.依鲁替尼，一种磷酸肌醇 3-激酶 p110δ 的抑制剂，用于治疗复发/难治性慢性淋巴细胞白血病。
Blood. 2014 May 29;123(22):3390-7. doi: 10.1182/blood-2013-11-535047. Epub 2014 Mar 10.
10
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.慢性淋巴细胞白血病中小 TP53 突变亚克隆的临床影响。
Blood. 2014 Apr 3;123(14):2139-47. doi: 10.1182/blood-2013-11-539726. Epub 2014 Feb 5.
Zotero 插件